CYDUCT Diagnostics’ HALO® Breast Fluid Collection System Cited in Peer-Reviewed Clinical Proteomics
The article spotlights HALO as advancing standardized breast fluid collection, supporting the growing interest in
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
The article spotlights HALO as advancing standardized breast fluid collection, supporting the growing interest in breast ductal molecular insights.
CYDUCT Diagnostics, Inc. (OTCMKTS:CYDX)
WESTPORT, CT, UNITED STATES, October 29, 2026 /EINPresswire.com/ — CYDUCT Diagnostics, Inc. (OTCPK: CYDX) (“CYDUCT” or the “Company”), a women’s health company developing technologies to support earlier detection and more precise breast health management, today announced that its HALO Automated Breast Fluid Collection System is cited in a peer-reviewed article published in Clinical Proteomics, a Springer Nature journal.
The review, “Nipple aspirate fluid as a proximal breast liquid biopsy platform: advancing precision risk management in breast cancer,” It identifies HALO as an example as a technology that has advanced the standardization of nipple aspirate fluid (NAF) collection. In discussing progress in breast fluid sampling, the authors write: “Further standardization has been achieved with automated devices (e.g., the HALO system)”
According to the article, the HALO system’s automated, programmed aspiration cycles are designed to minimize operator dependence and promote consistent breast-fluid collection across various clinical venues. The review further highlights the system’s demonstrated feasibility, safety, and high patient acceptance in large-scale screening studies involving asymptomatic women, providing an important foundation for future broader population-based clinical applications.
Independent Scientific Recognition of an Important Technological Advancement.
The citation of HALO in an independent scientific review reflects the role that CYDUCT’s HALO fluid collection system has played in the evolution of breast ductal fluid research.
“Seeing HALO cited in a peer-reviewed scientific journal is an important milestone for CYDUCT Diagnostics,” said Dominick Gatto, its CEO. “It underscores the scientific relevance of breast ductal fluid collection and our commitment to technologies that help clinicians better understand the biological environment where most breast cancers begin.”
Advancing the Science of Breast Ductal Fluid Analysis
The Clinical Proteomics review examines the emerging potential of NAF as a breast-specific source of molecular information. The authors describe NAF as a proximal liquid biopsy platform that can offer insight into the local ductal microenvironment through analysis of proteins, metabolites, genetic and epigenetic alterations, extracellular vesicles and other molecular signals.
Because most breast cancers originate within the ductal system, researchers are increasingly investigating whether molecular information collected directly from the ducts can complement imaging and other diagnostic approaches. The review highlights three promising areas:
• Molecular risk stratification for women with pathologic nipple discharge
• Individualized biological risk profiling for women at elevated risk or with dense breasts
• Monitoring of molecular changes associated with treatment response and disease progression
While the authors emphasize the need for greater standardization and prospective clinical validation, CYDUCT Diagnostics is committed to addressing these challenges through rigorous research, clinical innovation, and scalable technology development. Guided by a vision to transform breast healthcare, CYDUCT aims to advance these promising technologies from research into routine clinical practice, ultimately making precision risk assessment, earlier detection and personalized breast healthcare accessible to women everywhere.
Additional information will be available on the Company’s website at: www.CYDUCTDX.com.
FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION
This press release contains forward-looking statements, including statements regarding CYDUCT’s plans, expectations, beliefs, objectives and future performance. Such statements may be identified by words such as “may,” “could,” “will,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “potential” and similar expressions. Forward-looking statements are based on management’s current assumptions, estimates and information and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. Accordingly, such statements are not guarantees of future performance, and readers should not place undue reliance on them. Additional risks are described in the Company’s Annual Report and other filings with OTC Markets Group, available at www.otcmarkets.com. All forward-looking statements speak only as of the date of this release, and CYDUCT undertakes no obligation to update or revise them except as required by law.
CONTACT:
CYDUCT Diagnostics, Inc.
Investor Relations +1-888-545-9112
SOURCE: CYDUCT Diagnostics, Inc.
Elise Grubb
CYDUCT Diagnostics, Inc.
+1 800-388-6445
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
